Resumen de Pancreatic ductal adenocarcinoma: metastatic disease
Andrés Jesús Muñoz Martín, J. Adeva, J. Martinez Galán, J. J. Reina Zoiló, Manuel Hidalgo Medina
The treatment of choice of metastatic PADC is systemic chemotherapy. In the last decade, there have been significant advances in this area. New combination poli-chemotherapy schemes have shown a significant increase in overall survival and progression-free survival without impairing quality of life. In addition, the value of second-line chemotherapy treatment has consolidated and a new concept called “therapeutic sequencing” has also emerged. The aim of this article is to review the different therapeutic options in metastatic PDAC based on patient’s characteristics.
